

Rachel A Freedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7401121/publications.pdf>

Version: 2024-02-01

91
papers

3,565
citations

182225

30
h-index

169272

56
g-index

91
all docs

91
docs citations

91
times ranked

5597
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. <i>Breast</i> , 2022, 61, 77-83. | 0.9 | 38 |
| 2 | Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 307-309. | 0.8 | 29 |
| 3 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267. | 3.2 | 31 |
| 4 | Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study. , 2022, , . | | 0 |
| 5 | Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. <i>JCO Oncology Practice</i> , 2022, 18, 516-519. | 1.4 | 5 |
| 6 | Development of a workflow process mapping protocol to inform the implementation of regional patient navigation programs in breast oncology. <i>Cancer</i> , 2022, 128, 2649-2658. | 2.0 | 3 |
| 7 | Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 215-227. | 1.1 | 10 |
| 8 | Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 685-693. | 0.8 | 66 |
| 9 | Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 843-852. | 1.1 | 7 |
| 10 | Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 608-618. | 0.8 | 72 |
| 11 | Factors associated with late risks of breast cancer-specific mortality in the SEER registry. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 203-212. | 1.1 | 11 |
| 12 | Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609. | 3.4 | 15 |
| 13 | Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. <i>Cancer</i> , 2021, 127, 3310-3324. | 2.0 | 22 |
| 14 | Impact of race and socioeconomic status on breast cancer outcomes within the AJCC staging system.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18565-e18565. | 0.8 | 1 |
| 15 | Survival in male breast cancer (MaBC) over the past three decades.. <i>Journal of Clinical Oncology</i> , 2021, 39, 569-569. | 0.8 | 0 |
| 16 | Acceptability of a patient decision aid for women aged 70 and older with stage I, estrogen receptor-positive, HER2-negative breast cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 724-730. | 0.5 | 4 |
| 17 | Feasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, , . | 1.1 | 1 |
| 18 | A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 411-423. | 1.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 19 | Oncologistsâ€™ perspectives on omission of sentinel lymph node biopsy in women >70 years with early-stage hormone receptor-positive breast cancer.. Journal of Clinical Oncology, 2021, 39, 48-48. | 0.8 | 6 |
| 20 | Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal of the National Cancer Institute, 2021, 113, 355-359. | 3.0 | 10 |
| 21 | Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. Ca-A Cancer Journal for Clinicians, 2021, 71, 78-92. | 157.7 | 230 |
| 22 | Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer, 2020, 20, 145-151.e2. | 1.1 | 21 |
| 23 | Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. Oncologist, 2020, 25, 310-318. | 1.9 | 92 |
| 24 | Menopausal Hormone Therapy and Long-term Breast Cancer Risk. JAMA - Journal of the American Medical Association, 2020, 324, 347. | 3.8 | 4 |
| 25 | Translating research into practice: Protocol for a community-engaged, stepped wedge randomized trial to reduce disparities in breast cancer treatment through a regional patient navigation collaborative. Contemporary Clinical Trials, 2020, 93, 106007. | 0.8 | 15 |
| 26 | HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687. | 7.7 | 149 |
| 27 | Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. Oncologist, 2019, 24, 595-602. | 1.9 | 8 |
| 28 | Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. Cancer, 2019, 125, 4532-4540. | 2.0 | 11 |
| 29 | Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. Journal of Geriatric Oncology, 2019, 10, 980-986. | 0.5 | 11 |
| 30 | Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discovery, 2019, 9, 1208-1227. | 7.7 | 81 |
| 31 | Examining Associations of Racial Residential Segregation With Patient Knowledge of Breast Cancer and Treatment Receipt. Clinical Breast Cancer, 2019, 19, 178-187.e3. | 1.1 | 5 |
| 32 | Clinical Impact of Second Opinion Radiology Consultation for Patients With Breast Cancer. Journal of the American College of Radiology, 2019, 16, 814-823. | 0.9 | 8 |
| 33 | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2019, 37, 1081-1089. | 0.8 | 251 |
| 34 | Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer. Clinical Breast Cancer, 2019, 19, 200-207.e1. | 1.1 | 17 |
| 35 | Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. Journal of Medical Genetics, 2019, 56, 39-42. | 1.5 | 25 |
| 36 | Modeling accrual of older adults to cancer clinical trials: (Alliance A151736).. Journal of Clinical Oncology, 2019, 37, e18132-e18132. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.. Journal of Clinical Oncology, 2019, 37, 540-540. | 0.8 | 0 |
| 38 | Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.. Journal of Clinical Oncology, 2019, 37, 549-549. | 0.8 | 3 |
| 39 | Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer, 2018, 124, 2184-2191. | 2.0 | 46 |
| 40 | Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602). Oncologist, 2018, 23, 1016-1023. | 1.9 | 29 |
| 41 | Treatment Patterns Among Women Diagnosed With Stage I-III Triple-negative Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 997-1007. | 0.6 | 3 |
| 42 | Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt. Breast Cancer Research and Treatment, 2018, 167, 555-566. | 1.1 | 23 |
| 43 | Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- Advanced breast cancer: a review. Breast Cancer Research and Treatment, 2018, 167, 607-614. | 1.1 | 18 |
| 44 | Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Annals of Surgery, 2017, 265, 581-589. | 2.1 | 238 |
| 45 | Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncology, 2017, 3, 1043. | 3.4 | 98 |
| 46 | Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. Oncologist, 2017, 22, 386-393. | 1.9 | 38 |
| 47 | Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Research and Treatment, 2017, 164, 515-525. | 1.1 | 9 |
| 48 | Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?. JAMA Oncology, 2017, 3, 402. | 3.4 | 27 |
| 49 | Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer. Clinical Cancer Research, 2017, 23, 2647-2654. | 3.2 | 25 |
| 50 | Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013. Breast Cancer Research and Treatment, 2017, 166, 583-592. | 1.1 | 12 |
| 51 | Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 316-324. | 2.3 | 3 |
| 52 | Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5687-5695. | 3.2 | 170 |
| 53 | Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors. Cancer, 2017, 123, 1249-1258. | 2.0 | 87 |
| 54 | Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Research and Treatment, 2017, 161, 363-373. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. <i>BioResearch Open Access</i> , 2017, 6, 159-168. | 2.6 | 10 |
| 56 | Implementation of Surgeon-Initiated Gene Expression Profile Testing (OncoDX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. <i>Journal of Oncology Practice</i> , 2017, 13, e815-e820. | 2.5 | 14 |
| 57 | Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process. <i>Journal of Oncology Practice</i> , 2017, 13, e273-e282. | 2.5 | 30 |
| 58 | Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy. <i>Journal of Clinical Oncology</i> , 2017, 35, 3123-3130. | 0.8 | 27 |
| 59 | Location Isn't Everything: Proximity, Hospital Characteristics, Choice of Hospital, and Disparities for Breast Cancer Surgery Patients. <i>Health Services Research</i> , 2016, 51, 1561-1583. | 1.0 | 32 |
| 60 | Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. <i>Ecological Management and Restoration</i> , 2016, 30, 1-8. | 0.2 | 1 |
| 61 | Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment. <i>Journal of Oncology Practice</i> , 2016, 12, e613-e625. | 2.5 | 18 |
| 62 | Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 151-162. | 1.1 | 18 |
| 63 | Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 395-405. | 1.1 | 37 |
| 64 | Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey. <i>Clinical Breast Cancer</i> , 2016, 16, 105-112. | 1.1 | 13 |
| 65 | Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1190-1196. | 0.8 | 114 |
| 66 | Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952. | 0.8 | 148 |
| 67 | Factors associated with radiation therapy incompleteness for patients with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 187-199. | 1.1 | 10 |
| 68 | The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. <i>Cancer</i> , 2015, 121, 4333-4340. | 2.0 | 23 |
| 69 | How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. <i>Journal of Oncology Practice</i> , 2015, 11, 313-318. | 2.5 | 5 |
| 70 | Treatment of Breast Cancer in the Elderly. <i>Current Oncology Reports</i> , 2015, 17, 51. | 1.8 | 19 |
| 71 | Racial/Ethnic Differences in Patients' Selection of Surgeons and Hospitals for Breast Cancer Surgery. <i>JAMA Oncology</i> , 2015, 1, 222. | 3.4 | 33 |
| 72 | Racial/ethnic disparities in knowledge about one's breast cancer characteristics. <i>Cancer</i> , 2015, 121, 724-732. | 2.0 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Black/White Disparities in Receipt of Treatment and Survival Among Men With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2337-2344. | 0.8 | 37 |
| 74 | Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 697-707. | 1.1 | 32 |
| 75 | Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. <i>Journal of Geriatric Oncology</i> , 2014, 5, 2-7. | 0.5 | 5 |
| 76 | Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 927-934. | 0.8 | 88 |
| 77 | Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 491-501. | 1.1 | 42 |
| 78 | Management of breast cancer in very young women. <i>Breast</i> , 2013, 22, S176-S179. | 0.9 | 56 |
| 79 | Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 607-616. | 1.1 | 25 |
| 80 | A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 405-414. | 1.1 | 60 |
| 81 | Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. <i>Cancer</i> , 2013, 119, 839-846. | 2.0 | 60 |
| 82 | Racial/Ethnic Differences in Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care?. <i>Health Services Research</i> , 2013, 48, 1669-1683. | 1.0 | 32 |
| 83 | Receipt of locoregional therapy among young women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 893-906. | 1.1 | 33 |
| 84 | Reply to receipt of adjuvant breast cancer therapy in minority women. <i>Cancer</i> , 2012, 118, 865-865. | 2.0 | 0 |
| 85 | Treatment of Breast Cancer Brain Metastases. <i>Current Breast Cancer Reports</i> , 2012, 4, 1-9. | 0.5 | 10 |
| 86 | Adjuvant therapies for very young women with early stage breast cancer. <i>Breast</i> , 2011, 20, S146-S149. | 0.9 | 10 |
| 87 | A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and Brain Metastases. <i>Clinical Breast Cancer</i> , 2011, 11, 376-383. | 1.1 | 42 |
| 88 | The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. <i>Cancer</i> , 2011, 117, 180-189. | 2.0 | 172 |
| 89 | Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. <i>Breast</i> , 2010, 19, 69-75. | 0.9 | 12 |
| 90 | Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 713-719. | 0.8 | 143 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Glioblastoma in a Patient With Early-Stage Tonsil Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2848-2850. | 0.8 | 5 |